Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial

Abstract Background Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited. Hypothesis/Objective Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug‐eluting bead transarterial chemoembolization (D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cleo P. Rogatko, Chick Weisse, Tobias Schwarz, Allyson C. Berent, Marcio A. Diniz
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	DEB doxorubicin interventional radiology liver TACE Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/0f4caad1642742b2943013a44270c57c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f4caad1642742b2943013a44270c57c
record_format	dspace
spelling	oai:doaj.org-article:0f4caad1642742b2943013a44270c57c2021-11-30T17:01:04ZDrug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial1939-16760891-664010.1111/jvim.16109https://doaj.org/article/0f4caad1642742b2943013a44270c57c2021-05-01T00:00:00Zhttps://doi.org/10.1111/jvim.16109https://doaj.org/toc/0891-6640https://doaj.org/toc/1939-1676Abstract Background Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited. Hypothesis/Objective Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and short‐term CT assessment would demonstrate stable disease or partial response. Animals Client‐owned dogs (n = 16) with nonresectable HC. Methods Prospective, single‐arm clinical trial. Drug‐eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12 weeks after initial treatment. Results Drug‐eluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8/13; 62%) was the most common outcome followed by partial response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days (range, 39‐125) after initial treatment. Median tumor volume (mL) after DEB‐TACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7/27 (26%) treatments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatment‐induced death after 2/27 (7%) treatments. Median survival time after treatment was 337 days (range, 22‐1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly shorter median survival time (126 days; range, 46‐337) than those dogs without prior history of weight loss (582 days; range, 22‐1061). Conclusions Drug‐eluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample.Cleo P. RogatkoChick WeisseTobias SchwarzAllyson C. BerentMarcio A. DinizWileyarticleDEBdoxorubicininterventional radiologyliverTACEVeterinary medicineSF600-1100ENJournal of Veterinary Internal Medicine, Vol 35, Iss 3, Pp 1487-1495 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	DEB doxorubicin interventional radiology liver TACE Veterinary medicine SF600-1100
spellingShingle	DEB doxorubicin interventional radiology liver TACE Veterinary medicine SF600-1100 Cleo P. Rogatko Chick Weisse Tobias Schwarz Allyson C. Berent Marcio A. Diniz Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
description	Abstract Background Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited. Hypothesis/Objective Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and short‐term CT assessment would demonstrate stable disease or partial response. Animals Client‐owned dogs (n = 16) with nonresectable HC. Methods Prospective, single‐arm clinical trial. Drug‐eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12 weeks after initial treatment. Results Drug‐eluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8/13; 62%) was the most common outcome followed by partial response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days (range, 39‐125) after initial treatment. Median tumor volume (mL) after DEB‐TACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7/27 (26%) treatments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatment‐induced death after 2/27 (7%) treatments. Median survival time after treatment was 337 days (range, 22‐1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly shorter median survival time (126 days; range, 46‐337) than those dogs without prior history of weight loss (582 days; range, 22‐1061). Conclusions Drug‐eluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample.
format	article
author	Cleo P. Rogatko Chick Weisse Tobias Schwarz Allyson C. Berent Marcio A. Diniz
author_facet	Cleo P. Rogatko Chick Weisse Tobias Schwarz Allyson C. Berent Marcio A. Diniz
author_sort	Cleo P. Rogatko
title	Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
title_short	Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
title_full	Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
title_fullStr	Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
title_full_unstemmed	Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
title_sort	drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: a prospective clinical trial
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/0f4caad1642742b2943013a44270c57c
work_keys_str_mv	AT cleoprogatko drugelutingbeadchemoembolizationforthetreatmentofnonresectablehepaticcarcinomaindogsaprospectiveclinicaltrial AT chickweisse drugelutingbeadchemoembolizationforthetreatmentofnonresectablehepaticcarcinomaindogsaprospectiveclinicaltrial AT tobiasschwarz drugelutingbeadchemoembolizationforthetreatmentofnonresectablehepaticcarcinomaindogsaprospectiveclinicaltrial AT allysoncberent drugelutingbeadchemoembolizationforthetreatmentofnonresectablehepaticcarcinomaindogsaprospectiveclinicaltrial AT marcioadiniz drugelutingbeadchemoembolizationforthetreatmentofnonresectablehepaticcarcinomaindogsaprospectiveclinicaltrial
_version_	1718406426448101376

Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial

Ejemplares similares